A Phase 1/2 interventional study of ranibizumab 0.5 or 0.3 mg/0.05 cc in Polypoidal Choroidal Vasculopathy, sponsored by Southeast Retina Center, Georgia. Completed at 1 site in United States. Open to participants aged 35 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-16.
Sponsored by Southeast Retina Center, Georgia · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Polypoidal Choroidal Vasculopathy · United States.
Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2006, is one of 5 in phase 1/2, and was the 3rd registered.
55 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 7 are open to participants now.
Browse Polypoidal Choroidal Vasculopathy studies →1 of the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States is open now. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 7–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Polypoidal Choroidal Vasculopathy studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 35 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 4 2
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 50 across 40 interventional studies indexed under Polypoidal Choroidal Vasculopathy.
Median enrollment 20 across the 12 interventional studies, 150 across the 1 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 9 most frequent:
Southeast Retina Center, Georgia is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Southeast Retina Center, Georgia has 3 studies filed under Polypoidal Choroidal Vasculopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of tiny, abnormal blood vessels under the retina. These abnormal blood vessels can bleed or leak fluid, causing disruption of normal retinal function and vision loss. Ranibizumab is a drug that is FDA-approved for the treatment of wet age-related macular degeneration (AMD) and is injected directly into the eye. Given the efficacy of ranibizumab in the treatment of wet AMD, and the postulated similarity between the disease mechanisms involved in both wet AMD and PCV, we believe ranibizumab will have a beneficial effect on visual function in patients with PCV.
Please see above description. Phase I/II safety study; prospective, open-label, single-center, non-randomized, uncontrolled, consecutive interventional case series. Enrolled patients are >35 years old and display exudative, active polypoidal choroidal vasculopathy (PCV) in 1 eye. PCV is defined as choroidal neovascularization that displays occult characteristics on fluorescein angiography and polypoidal interconnecting vascular channels with saccular dilatations on indocyanine green angiography and/or fluorescein angiography. Eyes receive 3 consecutive, monthly intravitreal ranibizumab injections (0.5 mg or 0.3 mg/0.05 cc) followed by monthly evaluations with the option of additional intravitreal ranibizumab or alternative treatments at the discretion of the investigator. Baseline and follow-up evaluations include medical history, blood pressure, physical examination, early treatment diabetic rentinopathy study (ETDRS) best-corrected visual acuity (BCVA), intraocular pressure measurement, complete ophthalmologic examination, fundus photography, fluorescein/ indocyanine green (ICG) angiography, and optical coherence tomography (OCT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intraocular injection of 0.5 mg/ 0.05 cc ranibizumab
Drug: ranibizumab 0.5 or 0.3 mg/0.05 cc
Intraocular injection of 0.3 mg/ 0.05 cc ranibizumab
Drug: ranibizumab 0.5 or 0.3 mg/0.05 cc
Drug page: RanibizumabStudies of RanibizumabRanibizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
Also known as: Lucentis
Commonly Reported and Notable Adverse Events
Incidence and severity of ocular adverse events, as identified by indirect and direct examination. Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more of clinical macula (arcade to arcade), disease-related vitreous hemorrhage, injection-related endopthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.
Time frame: 2 years
Twenty subjects from one site in the United States will be enrolled. Subjects with active, exudative-PCV who have provided informed consent will be eligible. Date of first subject enrolled: May 19, 2006. Date of last subject enrolled: October 8, 2008.
| Milestone | Intraocular Injection 0.5 mg Ranibizumab | Intraocular Injection 0.3 mg Ranibizumab |
|---|---|---|
| Started | 10 | 10 |
| Completed | 9 | 7 |
| Not completed | 1 | 3 |
| Withdrew: Lost to follow-up | 1 | 3 |
Incidence and severity of ocular adverse events, as identified by indirect and direct examination. Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more of clinical macula (arcade to arcade), disease-related vitreous hemorrhage, injection-related endopthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.
| participants | Ranibizumab 0.5 mg | Ranibizumab 0.3 mg |
|---|---|---|
| Spider webs | 1 | 2 |
| Eye pain, burning | 2 | 3 |
| Wavy Lines | 1 | 2 |
| Seeing Dark spots | 2 | 2 |
| Flashes of Light | 1 | 1 |
| Floaters | 4 | 1 |
| Worsening visual acuity | 2 | 1 |
| Eye irritation | 1 | 2 |
| Mild Vitreous Hemorrhage | 1 | 2 |
| Blurry vision | 2 | 3 |
| Eyelid swelling | 2 | 1 |
| Transient increased blood pressure | 0 | 2 |
| Injection-related pain | 2 | 3 |
| Injection-related eyelid swelling | 2 | 1 |
| Macular hole | 0 | 1 |
| Transient increased intraocular pressure | 0 | 1 |
| Chalazion | 1 | 0 |
| Stye | 2 | 0 |
| Decreased color vision | 0 | 1 |
| Foreign Body Sensation | 1 | 0 |
| Posterior Vitreous detachment | 0 | 1 |
| Retinal Pigment epithelial changes | 0 | 1 |
| Worsened Night Vision | 1 | 0 |
| Worsened polypoidal choroidal vasculopathy | 1 | 0 |
| Worsening of Cataracts | 1 | 2 |
| Itchy, watery eyes | 1 | 2 |
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg | — | 0/10 (0%) | 9/10 (90%) |
| Ranibizumab 0.3 mg | — | 0/10 (0%) | 8/10 (80%) |
| Event | Ranibizumab 0.5 mg | Ranibizumab 0.3 mg |
|---|---|---|
| FloatersEye disorders | 4/10 | 1/10 |
| Injection Site PainEye disorders | 2/10 | 3/10 |
| Ocular BlurrinessEye disorders | 2/10 | 3/10 |
| Worsening of CataractEye disorders | 1/10 | 2/10 |
| Itchy, Watery EyesEye disorders | 1/10 | 2/10 |
| Vitreous HemorrhageEye disorders | 1/10 | 2/10 |
| Seeing Dark SpotsEye disorders | 2/10 | 2/10 |
| Worsened Visual AcuityEye disorders | 2/10 | 1/10 |
| Eyelid SwellingEye disorders | 2/10 | 1/10 |
| StyeEye disorders | 2/10 | 0/10 |
10 subjects were enrolled into each of the two ranibizumab groups (0.3 mg/ 0.5 mg)
| Age, Categorical(Participants) | Ranibizumab 0.5 mg/ 0.05 cc | Ranibizumab 0.3 mg/ 0.05 cc | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 7 | 11 |
| >=65 years | 6 | 3 | 9 |
| Age, Continuous(years) | Ranibizumab 0.5 mg/ 0.05 cc | Ranibizumab 0.3 mg/ 0.05 cc | Total |
|---|---|---|---|
| Mean | 64 ± 14 | 65 ± 8 | 64 ± 11 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5 mg/ 0.05 cc | Ranibizumab 0.3 mg/ 0.05 cc | Total |
|---|---|---|---|
| Female | 5 | 7 | 12 |
| Male | 5 | 3 | 8 |
| Region of Enrollment(participants) | Ranibizumab 0.5 mg/ 0.05 cc | Ranibizumab 0.3 mg/ 0.05 cc | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
The record gives a start of May 2006, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Polypoidal Choroidal Vasculopathy →
Southeast Retina Center, Georgia